一种具有持续药物释放的脂质体乙胺有效地缓解了与治疗相关的白血病
Yan Xiong1, Lei Xie2, Lingfeng Tang2
1The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, China.
International journal of pharmaceutics
|September 23, 2023
概括
纳米载体通过提供持续的药物释放来降低埃托化物 (VP16) 诱导的白血病. 与自由VP16相比,脂质体VP16的毒性降低,抗瘤功效提高.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 乙胺 (VP16) 是一种与治疗相关的白血病相关的化疗剂.
- 延长剂量计划可能会降低白血病发生风险.
- 基于纳米载体的药物输送提供了可控释放和降低毒性的潜力.
研究的目的:
- 通过持续的药物释放来研究纳米载体是否可以减轻VP16诱导的白血病发生.
- 为了比较脂质体VP16与自由VP16的毒性和抗瘤功效.
主要方法:
- 用VP16加载的脂质体被用与VP16-maleimide结合物的谷氨梯度方法构建.
- 在多次注射后评估了毒性,包括白血病的迹象.
- 活体抗瘤疗效被评估在LLC肺癌移植中.
主要成果:
- 自由VP16诱导了严重的白血病产生效应,包括脊髓巨变和淋巴细胞瘤.
- 脂质体VP16显著缓解了VP16诱导的白血病发生.
- 与同等剂量的自由VP16相比,脂质体VP16显示出增强的抗瘤活性.
结论:
- 从脂质体VP16中持续释放的药物有效地减少了白血病发生毒性.
- 脂质体VP16为传统VP16注射提供了一个更安全的替代方案,具有更好的疗效.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


